Latest Period
Q2 2026
Security Snapshot
Artiva Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARTV) Institutional Ownership
CUSIP: 04317A107
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
72
Shares (Excl. Options)
40,374,442
Price
$9.70
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ARTV on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 40,374,442
- Total 13F value
- $391,631,977
- Portfolio coverage rank
- 0%
- Share change
- +23,539,370
- Value change
- +$230,801,749
- Number of holders
- 72
- Shares outstanding
- 48,657,048
- SEC-reported price per share
- $11.30
- Insider filing price
- $11.30
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ARTV - Artiva Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 04317A107.
- 72 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 39 to 72 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $108,418,693 to $391,631,977.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 72 institutions filings for Q2 2026.
Security key
04317A107
Latest holder period
Q2 2026
13F holders
72
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
ARTV full holder history
Artiva Biotherapeutics, Inc. SEC filings
Artiva Biotherapeutics, Inc. company facts
Artiva Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04317A107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ARTV
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 38% | +3.5% | $178,634,773 | +$5,862,030 | 18,415,956 | +3.4% | RA Capital Management, L.P. | 22 Jul 2026 |
| GC Corp. | 12% | $70,376,516 | 5,999,703 | GC Corp | 11 May 2026 | |||
| VIKING GLOBAL INVESTORS LP | 5.4% | $30,546,867 | 2,604,166 | VIKING GLOBAL INVESTORS LP | 11 May 2026 | |||
| 5AM Ventures VI, L.P. | 4.8% | $21,015,005 | 2,353,304 | Andrew J. Schwab | 30 Jun 2026 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | $18,249,312 | 2,043,596 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2026 | |||
| venBio Global Strategic Fund III, L.P. | 4.9% | $2,937,489 | 1,198,975 | venBio Global Strategic Fund III, L.P. | 31 Mar 2025 | |||
| BlackRock, Inc. | 2% | -62% | $714,019 | -$1,116,882 | 485,727 | -61% | BlackRock, Inc. | 30 Jun 2025 |
As of 30 Jun 2026, 72 institutional investors reported holding 40,374,442 shares of Artiva Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARTV). This represents 83% of the company’s total 48,657,048 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
80%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 37% | 17,955,642 | +82% | 1.5% | $174,169,727 |
| VIKING GLOBAL INVESTORS LP | 5.4% | 2,604,166 | 0.07% | $25,260,410 | |
| Blackstone Inc. | 4.9% | 2,403,437 | 0.08% | $23,313,339 | |
| 5AM Venture Management, LLC | 4.8% | 2,353,304 | 0% | 7.9% | $22,827,049 |
| Venrock Adviser, LLC | 4.2% | 2,043,596 | +27% | 0.6% | $19,822,881 |
| FRANKLIN RESOURCES INC | 4.1% | 1,997,223 | +284% | 0% | $19,373,063 |
| Caligan Partners LP | 3.6% | 1,736,111 | 0.81% | $16,840,277 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2% | 981,815 | +373% | 0% | $9,523,606 |
| SAMSARA BIOCAPITAL, LLC | 2% | 954,861 | 0.76% | $9,262,152 | |
| Blue Owl Capital Holdings LP | 1.8% | 874,542 | 1.3% | $8,483,057 | |
| Propel Bio Management, LLC | 1.4% | 696,436 | +376% | 3.5% | $6,755,429 |
| BlackRock, Inc. | 1.4% | 694,726 | +226% | 0% | $6,738,842 |
| CITADEL ADVISORS LLC | 1.3% | 609,376 | +3740% | 0% | $5,910,947 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.1% | 525,000 | 0.57% | $5,092,500 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.73% | 353,845 | +248% | 0% | $3,433,947 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.65% | 314,375 | 0.06% | $3,049,438 | |
| Nantahala Capital Management, LLC | 0.62% | 300,000 | 0.18% | $2,910,000 | |
| Revelation Capital Management, LLC | 0.62% | 299,311 | 0% | 2.7% | $2,903,317 |
| Alyeska Investment Group, L.P. | 0.56% | 273,615 | +174% | 0.01% | $2,654,066 |
| ACUTA CAPITAL PARTNERS, LLC | 0.54% | 260,416 | 1.8% | $2,526,035 | |
| KVP Capital Advisors, LP | 0.41% | 200,000 | 1.4% | $1,940,000 | |
| WELLINGTON MANAGEMENT GROUP LLP | 0.4% | 194,108 | 0% | 0% | $1,882,848 |
| UBS Group AG | 0.38% | 184,020 | +11951% | 0% | $1,784,994 |
| SEVEN GRAND MANAGERS, LLC | 0.36% | 175,000 | 0.07% | $1,697,500 | |
| STATE STREET CORP | 0.34% | 165,764 | +363% | 0% | $1,607,911 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 40,374,442 | $391,631,977 | +$230,801,749 | $9.70 | 72 |
| 2026 Q1 | 16,834,066 | $108,418,693 | -$484,282 | $6.44 | 39 |
| 2025 Q4 | 16,956,116 | $72,741,648 | -$4,402,051 | $4.29 | 34 |
| 2025 Q3 | 18,152,764 | $52,098,905 | -$149,495 | $2.87 | 39 |
| 2025 Q2 | 18,507,398 | $27,946,001 | -$5,466,434 | $1.51 | 47 |
| 2025 Q1 | 20,919,533 | $62,758,401 | -$3,180,578 | $3.00 | 52 |
| 2024 Q4 | 21,161,524 | $213,249,951 | +$4,226,842 | $10.08 | 57 |
| 2024 Q3 | 20,729,707 | $319,393,001 | +$306,409,253 | $15.45 | 49 |